A Study of SGT-212 Gene Therapy in Friedreich's Ataxia (FALCON)

Solid Biosciences

Status and phase: Enrolling; Phase 1

Conditions: Friedreich's Ataxia (FA)

Treatments: Drug: SGT-212

Study type: Interventional

Funder types: Industry

Identifiers

NCT07180355

SGT-212-101

Details and patient eligibility

About

This is a phase 1b, first in-human, open-label, dose-finding study investigating the safety and tolerability of SGT-212 in participants with Friedreich's ataxia (FA). It will be delivered via dual intradentate nucleus (IDN) and intravenous (IV) administration to participants with FA.

All participants will receive SGT-212 and will be enrolled in the study for approximately 5 years.

Enrollment: 10 estimated patients

Sex: All

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Has history of FA symptom onset ≤25 years of age

• Has a clinical and genetic diagnosis of FA

• Has a staging score of ≥1 but <6 on the Friedreich's Ataxia Rating Scale (FARS) Functional Disability Staging Score

• Is willing to agree to the following rules for use of omaveloxolone (Skyclarys):

  1. For a candidate who is currently taking omaveloxolone, has been on a stable dose for 12 weeks, expects to continue taking omaveloxolone at that dose throughout the study, and is willing to stop taking omaveloxolone at the direction of the Investigator or Sponsor's Medical Monitor if evidence of transaminitis or synthetic liver dysfunction is detected during the study
  2. For a candidate who is not actively taking omaveloxolone, at least 12 weeks have passed since the last dose and the candidate agrees not to resume omaveloxolone during the 18-month period after SGT-212 infusion NOTE: The use of any other approved or investigational medicinal product for the treatment of FA should be discussed with the study team.

Exclusion criteria

• Antibodies against adeno-associated virus serotype 9 (AAV9)
• Has a modified FARS (mFARS) score <20
• Has a body weight ≤25 kilogram (kg) or has body mass index (BMI) ≥33 kg/m^2
• Has a contraindication to endomyocardial biopsy (EMB) or cardiac catheterization
• Is unable to undergo cardiac and brain MRI with contrast, including hypersensitivity to gadolinium contrast agent, presence of a non-MRI-compatible cardiac pacemaker, presence of a non-MRI-compatible implantable cardiac defibrillator, or physical condition (e.g., contractures)
• Has uncontrolled diabetes as defined by a hemoglobin (Hb) A1c >9%
• Has participated in recent interventional clinical studies or received any investigational therapy administered within 3 months or 5 half-lives (whichever is longer) prior to Screening
• Has received gene therapy at any time
• Has contraindications to receiving corticosteroids
• Has any contraindication to the surgical procedures involved with IDN infusion of SGT-212
• Has any known cardiac disease not related to FA including known obstructive coronary artery disease (CAD)
• Other Inclusion/Exclusion criteria to be applied as per protocol.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

10 participants in 3 patient groups

Cohort 1 (Non-Ambulatory)

Experimental group

Description:

Non-ambulatory participants will receive bilateral intradentate infusion (IDN) followed by systemic intravenous (IV) infusion.

Treatment:

Drug: SGT-212

Cohort 2 (Ambulatory)

Experimental group

Description:

Ambulatory participants will receive bilateral IDN infusion followed by systemic IV infusion.

Treatment:

Drug: SGT-212

Cohort 3 (Ambulatory and Non-Ambulatory)

Experimental group

Description:

Participants will receive bilateral IDN followed by systemic IV infusion.

Treatment:

Drug: SGT-212